Intervention of Chile to the TRIPS Council on Copyright Limitations and Exceptions
This statement was delivered by Chile on 5 June 2012 at the WTO TRIPS Council on copyright limitations and exceptions.
Agenda of TRIPS Council meeting (5-6 June 2012): Information exchange on counterfeits, WIPO negotiations on copyright L&Es
The following WTO airgram WTO/AIR/3943/REV.1 (23 May 2012) contains the agenda for the upcoming WTO Council for TRIPS meeting to be held in Geneva from Tuesday, 5 June 2012 to Wednesday, 6 June 2012. The airgram notes that the United States has made a written request for an agenda item on the “exchange of information on securing supply chains against counterfeit goods” (agenda item K). Brazil and the United States made a joint request for an additional agenda item (L) on “copyright limitations and exceptions: ongoing negotiations at WIPO-Briefing by Brazil and the United States”. Continue Reading
What’s a counterfeit? And how many counterfeit drugs are there?
Donald McNeil has an article in the New York Times that appeared in print on May 22, 2012 (page D6 of the New York edition) with the headline: “Malaria: Fake and Substandard Drugs Grow as Threat to Fight Disease.” A web version is available here: http://www.nytimes.com/2012/05/22/health/policy/fake-and-substandard-drugs-grow-as-threat-to-fight-malaria.html
1 Open letter to those who collectively produced the May 23, 2012 statement to the WIPO SCP on the topics of patents and health
Open letter to those who collectively produced the May 23, 2012 statement to the WIPO SCP on the topics of patents and health (Copy of US statement available here: https://www.keionline.org/node/1416).
May 25, 2012
To each and everyone who worked on the SCP submission:
This letter outlines our concerns to the May 23, 2012 statement to the 18th Session of the World Intellectual Property Organization (WIPO) Standing Committee on the Law of Patents (SCP), on the agenda for patents and health.
In its opening, the USPTO said the following:
1 US statement to SCP 18 on the United States proposal on Patents and Health
The following is the statement read today by USPTO during a meeting of the WIPO Standing Committee on the Law of Patent, on the agenda item for patents and health. I’ll provide more commentary later, but in general, this was seen an aggressive attack on a proposal for work by the Development Agenda Group (DAG), and on the notion that countries should grant compulsory licenses on patents to address concerns over access or affordability of drugs.
[Update: KEI wrote to USPTO about the submission: /node/1420]
The USPTO statement follows:
SCP18More notes on the USTR 2012 Special 301 List
The USTR’s 2012 Special 301 list was published on April 30, 2012. Below are some comments about certain portions of the Special 301 Report that concern access to knowledge and access to medicines.
USTR cites the “TEAM” approach to access to medicines
Continue ReadingUSTR’s 2012 Special 301 Report, focuses on largest developing country markets, and Canada
The 2012 USTR Special 301 Report was published on April 30, 2012. The report details USTR’s unilateral standards for the granting and enforcement for a diverse set of intellectual property rights, and singles out countries that USTR claims do not… Continue Reading
KEI Notes From the Eleventh Round of TPPA negotiations in Melbourne, Australia
The eleventh round of negotiations for the Trans-Pacific Partnership Agreement (TPPA) took place in Melbourne, Australia from 1-9 March 2012. Stakeholders were given the opportunity to present at the stakeholder platform on 4 March, attend a reception on 6 March and the stakeholder briefing on 7 March.
1 KEI Statement on India’s granting of compulsory license to patents on cancer drug sorafenib (NATCO Vs. BAYER)
The India Controller General Controller General of Patents, Designs & Trade Marks has just (March 12, 2012) issued an order granting a compulsory license to patents on the cancer drug sorafenib/Nexavar, in the matter of NATCO Vs. BAYER. A copy of the decision is attached below.
KEI submission to WIPO patent committee commenting on the US proposal on patents and health
KEI submission to the WIPO Standing Committee on the Law of Patents (SCP) on Patents and Health
28 February 2012